口服抗凝剂治疗启动的最佳时间 后急性缺血性中风:叙述性综述
Nicholas Aderinto1, Lama H Aljamea2, Faisal H Aljamea3
1Medicine, Ladoke Akintola University of Technology, Ogbomoso, NGA.
Cureus
|October 28, 2025
概括
在缺血性中风后早期开始口服抗凝药对大多数患者来说是安全的,改善了结果并降低了死亡率. 根据中风严重程度和个体因素量身定制治疗时间是最佳结果的关键.
科学领域:
- 神经学 神经学
- 心脏病学 心脏病学
- 药理学 药理学是指药理学的学科.
背景情况:
- 在急性缺血性中风后,口服抗凝治疗至关重要.
- 平衡复发性中风预防和出血转变是非常重要的.
- 目前的指导方针建议在中风后4至14天之间开始治疗.
研究的目的:
- 审查当前关于口服抗凝药在急性缺血性中风后启动最佳时间的证据.
- 评估早期与延迟抗凝血的安全性和有效性.
- 根据中风特征,为以患者为中心的治疗策略提供信息.
主要方法:
- 对指导方针和临床试验/观察性研究进行叙述性审查.
- 在PubMed,科学网络和谷歌学者 (2013-2025) 进行的文献搜索.
- 对最近的试验分析,如ELAN和TIMING.
主要成果:
- 轻微/中度性中风的早期启动 (48小时至5天内) 是安全的,可以改善功能结果和生存率.
- 延迟的抗凝血与血栓事件的增加有关,而没有增加的安全益处.
- 支持以患者为中心的方法,青早期治疗,除非存在禁忌.
结论:
- 早期的口服抗凝药通常对急性缺血性中风患者是安全和有益的.
- 脑卒中严重程度,成像和患者因素需要个性化的时间决定.
- 最近的证据支持了转向更早,量身定制的抗凝剂启动的转变.
相关概念视频
Venous Thrombosis III: Interprofessional Care
276
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
276
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
2.1K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
2.1K
Anticoagulant Drugs: Low-Molecular-Weight Heparins
1.6K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
1.6K
Acute Coronary Syndrome IV: Interprofessional Care
214
IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
214
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care
308
Diagnosing Pulmonary EmbolismDiagnosing pulmonary embolism (PE) involves clinical assessment and advanced imaging tests. The preferred diagnostic tool is the spiral (helical) CT scan or CT angiography (CTA), which uses intravenous contrast media to visualize the pulmonary vasculature and identify emboli.A ventilation-perfusion (V/Q) scan is an alternative for patients unable to receive contrast media. This scan includes both perfusion and ventilation scanning. Perfusion scanning involves...
308
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
1.1K
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
1.1K


